Biognosys cooperating with Boehringer Ingelheim

Biognosys is active in the area of proteomics and is working to decode the proteome, which refers to the entirety of proteins in a pre-defined unit, such as a cell or even a human being. This research work is designed to pave the way towards the production of more effective drugs. To this end, Biognosys has developed various approaches within the framework of mass spectrometry for the analysis of proteins, which will now be used for drug development applications in the cooperation agreed with Boehringer Ingelheim, as detailed in a press release issued by Biognosys.

In specific terms, the two companies will be conducting research into the disease known as idiopathic pulmonary fibrosis (IPF) on a preclinical murine model with the help of the Spectronaut software developed by Biognosys. The data collected via this collaboration should help the partners to develop a treatment approach to combat this chronic pulmonary disease. Oliver Rinner, CEO of Biognosys, was quoted in the press release, explaining that the cooperation reveals how proteomics technologies are becoming essential tools in drug discovery programs.

Biognosys is a spin-off of the Swiss Federal Institute of Technology in Zurich (ETH) and is headquartered in the Bio-Technopark Schlieren-Zurich.